PExAs technology, which enable non-invasive collection of proximal biomarkers for lung diseases, was selected among its peers since its contribution to the sphere is unique and a cut above competitors and industry peers.

MedTech Outlook"s selection panel, comprised of physicians, healthcare executives, and the magazine"s editorial board, chose from a list of candidates submitted through nominations and consultations with industry leaders to decide upon 20 companies that stood out in delivering today"s most innovative advancements in the field of medical technology.

Erik Ekbo, CEO at PExA AB:
- It is an honour to be recognized for our continuing efforts to provide value to basic science and Pharma R&D in the field of respiratory medicine, which is the first step in our attempts to pave the way for early detection and more personalized and effective treatment of various respiratory diseases.

The companies selected for the Top 20 list, can be found here along with a detailed feature on PExA which is found here, in the 2018 special edition of MedTech Outlook.

About MedTech Outlook:
MedTech Outlook is an enterprise technology magazine which reaches out to over 29,000 qualified subscribers. MedTech Outlook is the go-to resource for CMOs, senior-level medical experts, and decision makers to learn and share their experiences with products, technologies and medical technology trends. We provide a knowledge platform to senior executives to share their experiences and learn from each other along with short but in-depth articles about top providers in the Medical industry.

For further information, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
E-mail: erik@pexa.se

PExA AB (556956-9246) develops and markets a research instrument with associated products and services to lung researchers for simple and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be likened to a “blood test for the small airways”. The aim is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventors, key employees, business angels and GU Ventures. PExA’s B share is listed on Spotlight Stock Market